Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk. Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.

Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk to bring weight-loss drug Wegovy to its customers.